SCH CD-UNDESIGNATED GLUCAGON

Illinois General Assembly - Full Text of SB3051

Select Language

×

The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.

Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.

The English language version is always the official and authoritative version of this website.

NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.

Choose Language

English

Afrikaans

Albanian

Arabic

Armenian

Azerbaijani

Basque

Bengali

Bosnian

Catalan

Croatian

Czech

Danish

Dutch

Esperanto

Estonian

Filipino

Finnish

French

Galician

Georgian

German

Greek

Gujarati

Haitian Creole

Hausa

Hawaiian

Hebrew

Hindi

Hungarian

Icelandic

Indonesian

Interlingua

Interlingue

Inuktitut

Irish

Italian

Japanese

Javanese

Kannada

Khmer

Korean

Latin

Latvian

Lithuanian

Luxembourgish

Macedonian

Malagasy

Malayalam

Maltese

Maori

Marathi

Myanmar

Nepali

Norwegian

Odia

Pashto

Punjabi

Romanian

Russian

Samoan

Sango

Sanskrit

Sardinian

Sindhi

Sinhala

Slovak

Slovenian

Somali

Southern Sotho

Spanish

Sundanese

Swahili

Swedish

Tamil

Telugu

Thai

Tigrinya

Tonga

Turkish

Ukrainian

Urdu

Vietnamese

Welsh

Xhosa

Yiddish

Yoruba

Zulu

Powered by
Translate

Close

Illinois General Assembly

Top Navigation Bar

Translate

Learn

Select General Assembly

Search the 104th General Assembly

Enter search terms for legislation, members, committees, or schedules.

ILGA.GOV

LEGISLATION & LAWS

Bills & Resolutions

Public Acts

Illinois Compiled Statutes

Illinois Constitution

Search Legislation

Glossary

Guide

Reports & Inquiry

Legislative Reports

Special Reports

FTP Site

Legislator Lookup

Capitol Complex Phone Numbers

Rules & Regulations

Illinois Register

Administrative Rules

Senate

Members

Schedules

Committees

Request for Remote Testimony

Journals

Transcripts

Rules

Audio/Video

FOIA Information

Senate Employment Opportunities

Media Guidelines

House

Members

Schedules

Committees

Submit testimony for House Committees

Journals

Transcripts

Rules

Audio/Video

FOIA Information

House Employment Opportunities

Log In

Mobile Top Bar

Search the 104th General Assembly

Enter keywords to search the Illinois General Assembly website.

Full Text of SB3051

Home

Legislation

Full Text

SB3051 - 104th General Assembly

Bill Status

Full Text

Votes

Witness Slips

Select Menu

Bill Status

Full Text

Votes

Witness Slips

Printer Friendly Version

Introduced

Engrossed

Enrolled

Senate Amendment 001

Printer Friendly Version

Introduced

Engrossed

Enrolled

Senate Amendment 001

Open PDF

SB3051 Enrolled
LRB104 16562 LNS 29960 b
1

AN ACT concerning education.

2

Be it enacted by the People of the State of Illinois,
3
represented in the General Assembly:

4

Section 5.
The School Code is amended by changing Section
5
22-30 as follows:

6

(105 ILCS 5/22-30)
7

Sec. 22-30.
Administration and carry of

8
Self-administration and self-carry of asthma medication and
9
epinephrine injectors; administration of undesignated
10
epinephrine injectors; administration of an opioid antagonist;
11
administration of undesignated asthma
medication; supply of
12
undesignated oxygen tanks; asthma episode emergency response
13
protocol.
14

(a) For the purpose of this Section only, the following
15
terms shall have the meanings set forth below:
16

"Asthma action plan" means a written plan developed with a
17
pupil's medical provider to help control the pupil's asthma.
18
The goal of an asthma action plan is to reduce or prevent
19
flare-ups and emergency department visits through day-to-day
20
management and to serve as a student-specific document to be
21
referenced in the event of an asthma episode.
22

"Asthma episode emergency response protocol" means a
23
procedure to provide assistance to a pupil experiencing

SB3051 Enrolled
- 2 -
LRB104 16562 LNS 29960 b
1
symptoms of wheezing, coughing, shortness of breath, chest
2
tightness, or breathing difficulty.
3

"Epinephrine injector" includes an auto-injector approved
4
by the United States Food and Drug Administration for the
5
administration of epinephrine and a pre-filled syringe
6
approved by the United States Food and Drug Administration and
7
used for the administration of epinephrine that contains a
8
pre-measured dose of epinephrine that is equivalent to the
9
dosages used in an auto-injector.
10

"Asthma medication" means quick-relief asthma medication,
11
including albuterol or other short-acting bronchodilators,
12
that is approved by the United States Food and Drug
13
Administration for the treatment of respiratory distress.
14
"Asthma medication" includes medication delivered through a
15
device, including a metered dose inhaler with a reusable or
16
disposable spacer or a nebulizer with a mouthpiece or mask.
17

"Opioid antagonist" means a drug that binds to opioid
18
receptors and blocks or inhibits the effect of opioids acting
19
on those receptors, including, but not limited to, naloxone
20
hydrochloride or any other similarly acting drug approved by
21
the U.S. Food and Drug Administration.
22

"Respiratory distress" means the perceived or actual
23
presence of wheezing, coughing, shortness of breath, chest
24
tightness, breathing difficulty, or any other symptoms
25
consistent with asthma. Respiratory distress may be
26
categorized as "mild-to-moderate" or "severe".

SB3051 Enrolled
- 3 -
LRB104 16562 LNS 29960 b
1

"School nurse" means a registered nurse working in a
2
school with or without licensure endorsed in school nursing.
3

"Self-administration" means a pupil's discretionary use of
4
his or her prescribed asthma medication or epinephrine
5
injector.
6

"Self-carry" means a pupil's ability to carry his or her
7
prescribed asthma medication or epinephrine injector.
8

"Standing protocol" may be issued by (i) a physician
9
licensed to practice medicine in all its branches, (ii) a
10
licensed physician assistant with prescriptive authority, or
11
(iii) a licensed advanced practice registered nurse with
12
prescriptive authority.
13

"Trained personnel" means any school employee or volunteer
14
personnel authorized in Sections 10-22.34, 10-22.34a, and
15
10-22.34b of this Code who has completed training under
16
subsection (g) of this Section to recognize and respond to
17
anaphylaxis, an opioid overdose,
or
respiratory distress
, or a
18
severe hypoglycemia emergency
.
19

"Undesignated asthma medication" means asthma medication
20
prescribed in the name of a school district, public school,
21
charter school, or nonpublic school.
22

"Undesignated epinephrine injector" means an epinephrine
23
injector prescribed in the name of a school district, public
24
school, charter school, or nonpublic school.
25

"Undesignated glucagon" means a glucagon rescue therapy
26
approved by the United States Food and Drug Administration and

SB3051 Enrolled
- 4 -
LRB104 16562 LNS 29960 b
1
prescribed in the name of a school district, public school,
2
charter school, or nonpublic school for the treatment of
3
severe hypoglycemia in a dosage form that can be rapidly
4
administered to a person in an emergency, including prefilled
5
or nasally administered glucagon.

6

(b) A school, whether public, charter, or nonpublic, must
7
permit the self-administration and self-carry of asthma
8
medication by a pupil with asthma or the self-administration
9
and self-carry of an epinephrine injector by a pupil, provided
10
that:
11

(1) the parents or guardians of the pupil provide to
12

the school (i) written authorization from the parents or
13

guardians for (A) the self-administration and self-carry
14

of asthma medication or (B) the self-carry of asthma
15

medication or (ii) for (A) the self-administration and
16

self-carry of an epinephrine injector or (B) the
17

self-carry of an epinephrine injector, written
18

authorization from the pupil's physician, physician
19

assistant, or advanced practice registered nurse; and
20

(2) the parents or guardians of the pupil provide to
21

the school (i) the prescription label, which must contain
22

the name of the asthma medication, the prescribed dosage,
23

and the time at which or circumstances under which the
24

asthma medication is to be administered, or (ii) for the
25

self-administration or self-carry of an epinephrine
26

injector, a written statement from the pupil's physician,

SB3051 Enrolled
- 5 -
LRB104 16562 LNS 29960 b
1

physician assistant, or advanced practice registered nurse
2

containing the following information:
3

(A) the name and purpose of the epinephrine
4

injector;
5

(B) the prescribed dosage; and
6

(C) the time or times at which or the special
7

circumstances under which the epinephrine injector is
8

to be administered.
9
The information provided shall be kept on file in the office of
10
the school nurse or, in the absence of a school nurse, the
11
school's administrator.
12

(b-5) A school district, public school, charter school, or
13
nonpublic school may authorize the provision of a
14
student-specific or undesignated epinephrine injector to a
15
student or any personnel authorized under a student's
16
Individual Health Care Action Plan, allergy emergency action
17
plan, or plan pursuant to Section 504 of the federal
18
Rehabilitation Act of 1973 to administer an epinephrine
19
injector to the student, that meets the student's prescription
20
on file.
21

(b-10) The school district, public school, charter school,
22
or nonpublic school may authorize a school nurse or trained
23
personnel to do the following: (i) provide an undesignated
24
epinephrine injector to a student for self-administration only
25
or any personnel authorized under a student's Individual
26
Health Care Action Plan, allergy emergency action plan, plan

SB3051 Enrolled
- 6 -
LRB104 16562 LNS 29960 b
1
pursuant to Section 504 of the federal Rehabilitation Act of
2
1973, or individualized education program plan to administer
3
to the student that meets the student's prescription on file;
4
(ii) administer an undesignated epinephrine injector that
5
meets the prescription on file to any student who has an
6
Individual Health Care Action Plan, allergy emergency action
7
plan, plan pursuant to Section 504 of the federal
8
Rehabilitation Act of 1973, or individualized education
9
program plan that authorizes the use of an epinephrine
10
injector; (iii) administer an undesignated epinephrine
11
injector to any person that the school nurse or trained
12
personnel in good faith believes is having an anaphylactic
13
reaction; (iv) administer an opioid antagonist to any person
14
that the school nurse or trained personnel in good faith
15
believes is having an opioid overdose; (v) provide
16
undesignated asthma medication to a student for
17
self-administration only or to any personnel authorized under
18
a student's Individual Health Care Action Plan or asthma
19
action plan, plan pursuant to Section 504 of the federal
20
Rehabilitation Act of 1973, or individualized education
21
program plan to administer to the student that meets the
22
student's prescription on file; (vi) administer undesignated
23
asthma medication that meets the prescription on file to any
24
student who has an Individual Health Care Action Plan or
25
asthma action plan, plan pursuant to Section 504 of the
26
federal Rehabilitation Act of 1973, or individualized

SB3051 Enrolled
- 7 -
LRB104 16562 LNS 29960 b
1
education program plan that authorizes the use of asthma
2
medication;
and
(vii) administer undesignated asthma
3
medication to any person that the school nurse or trained
4
personnel believes in good faith is having respiratory
5
distress
; (viii) provide undesignated glucagon to any
6
personnel authorized under a student's Individual Health Care
7
Action Plan, in accordance with the student's prescriber's
8
order or Section 504 plan, individualized education program,
9
or other written accommodations plan, to administer glucagon
10
to the student; and (ix) administer undesignated glucagon to a
11
student in accordance with the student's prescriber's order,
12
Individual Health Care Action Plan, or Section 504 plan,
13
individualized education program, or other written
14
accommodations plan that authorizes the use of glucagon
.
15

(c) The school district, public school, charter school, or
16
nonpublic school must inform the parents or guardians of the
17
pupil, in writing, that the school district, public school,
18
charter school, or nonpublic school and its employees and
19
agents, including a physician, physician assistant, or
20
advanced practice registered nurse providing standing protocol
21
and a prescription for school epinephrine injectors, an opioid
22
antagonist,
or
undesignated asthma medication,
or undesignated
23
glucagon
are to incur no liability or professional discipline,
24
except for willful and wanton conduct, as a result of any
25
injury arising from the administration of asthma medication,
26
an epinephrine injector,
or
an opioid antagonist
, or glucagon,

SB3051 Enrolled
- 8 -
LRB104 16562 LNS 29960 b
1
regardless of whether authorization was given by the pupil's
2
parents or guardians or by the pupil's physician, physician
3
assistant, or advanced practice registered nurse. The parents
4
or guardians of the pupil must sign a statement acknowledging
5
that the school district, public school, charter school, or
6
nonpublic school and its employees and agents are to incur no
7
liability, except for willful and wanton conduct, as a result
8
of any injury arising from the administration of asthma
9
medication, an epinephrine injector,
or
an opioid antagonist
,
10
or glucagon,
regardless of whether authorization was given by
11
the pupil's parents or guardians or by the pupil's physician,
12
physician assistant, or advanced practice registered nurse
,

13
and that the parents or guardians must indemnify and hold
14
harmless the school district, public school, charter school,
15
or nonpublic school and its employees and agents against any
16
claims, except a claim based on willful and wanton conduct,
17
arising out of the administration of asthma medication, an
18
epinephrine injector,
or
an opioid antagonist
, or glucagon,

19
regardless of whether authorization was given by the pupil's
20
parents or guardians or by the pupil's physician, physician
21
assistant, or advanced practice registered nurse.
22

(c-5) When a school nurse or trained personnel administers
23
an undesignated epinephrine injector to a person whom the
24
school nurse or trained personnel in good faith believes is
25
having an anaphylactic reaction, administers an opioid
26
antagonist to a person whom the school nurse or trained

SB3051 Enrolled
- 9 -
LRB104 16562 LNS 29960 b
1
personnel in good faith believes is having an opioid overdose,
2
or administers undesignated asthma medication to a person whom
3
the school nurse or trained personnel in good faith believes
4
is having respiratory distress, notwithstanding the lack of
5
notice to the parents or guardians of the pupil or the absence
6
of the parents or guardians signed statement acknowledging no
7
liability, except for willful and wanton conduct, the school
8
district, public school, charter school, or nonpublic school
9
and its employees and agents, and a physician, a physician
10
assistant, or an advanced practice registered nurse providing
11
standing protocol and a prescription for undesignated
12
epinephrine injectors, an opioid antagonist,
or
undesignated
13
asthma medication,
or undesignated glucagon
are to incur no
14
liability or professional discipline, except for willful and
15
wanton conduct, as a result of any injury arising from the use
16
of an undesignated epinephrine injector, the use of an opioid
17
antagonist,
or
the use of undesignated asthma medication,
or
18
the use of undesignated glucagon,
regardless of whether
19
authorization was given by the pupil's parents or guardians or
20
by the pupil's physician, physician assistant, or advanced
21
practice registered nurse.
22

(d) The permission for self-administration and self-carry
23
of asthma medication or the self-administration and self-carry
24
of an epinephrine injector is effective for the school year
25
for which it is granted and shall be renewed each subsequent
26
school year upon fulfillment of the requirements of this

SB3051 Enrolled
- 10 -
LRB104 16562 LNS 29960 b
1
Section.
2

(e) Provided that the requirements of this Section are
3
fulfilled, a pupil with asthma may self-administer and
4
self-carry his or her asthma medication or a pupil may
5
self-administer and self-carry an epinephrine injector (i)
6
while in school, (ii) while at a school-sponsored activity,
7
(iii) while under the supervision of school personnel, or (iv)
8
before or after normal school activities, such as while in
9
before-school or after-school care on school-operated property
10
or while being transported on a school bus.
11

(e-5) Provided that the requirements of this Section are
12
fulfilled, a school nurse or trained personnel may administer
13
an undesignated epinephrine injector to any person whom the
14
school nurse or trained personnel in good faith believes to be
15
having an anaphylactic reaction (i) while in school, (ii)
16
while at a school-sponsored activity, (iii) while under the
17
supervision of school personnel, or (iv) before or after
18
normal school activities, such as while in before-school or
19
after-school care on school-operated property or while being
20
transported on a school bus. A school nurse or trained
21
personnel may carry undesignated epinephrine injectors on his
22
or her person while in school or at a school-sponsored
23
activity.
24

(e-10) Provided that the requirements of this Section are
25
fulfilled, a school nurse or trained personnel may administer
26
an opioid antagonist to any person whom the school nurse or

SB3051 Enrolled
- 11 -
LRB104 16562 LNS 29960 b
1
trained personnel in good faith believes to be having an
2
opioid overdose (i) while in school, (ii) while at a
3
school-sponsored activity, (iii) while under the supervision
4
of school personnel, or (iv) before or after normal school
5
activities, such as while in before-school or after-school
6
care on school-operated property. A school nurse or trained
7
personnel may carry an opioid antagonist on his or her person
8
while in school or at a school-sponsored activity.
9

(e-15) If the requirements of this Section are met, a
10
school nurse or trained personnel may administer undesignated
11
asthma medication to any person whom the school nurse or
12
trained personnel in good faith believes to be experiencing
13
respiratory distress (i) while in school, (ii) while at a
14
school-sponsored activity, (iii) while under the supervision
15
of school personnel, or (iv) before or after normal school
16
activities, including before-school or after-school care on
17
school-operated property. A school nurse or trained personnel
18
may carry undesignated asthma medication on his or her person
19
while in school or at a school-sponsored activity.
20

(e-20) A school nurse or trained personnel may carry
21
undesignated glucagon on his or her person while in school or
22
at a school-sponsored activity.

23

(f) The school district, public school, charter school, or
24
nonpublic school may maintain a supply of undesignated
25
epinephrine injectors in any secure location that is
26
accessible before, during, and after school where an allergic

SB3051 Enrolled
- 12 -
LRB104 16562 LNS 29960 b
1
person is most at risk, including, but not limited to,
2
classrooms and lunchrooms. A physician, a physician assistant
3
who has prescriptive authority in accordance with Section 7.5
4
of the Physician Assistant Practice Act of 1987, or an
5
advanced practice registered nurse who has prescriptive
6
authority in accordance with Section 65-40 of the Nurse
7
Practice Act may prescribe undesignated epinephrine injectors
8
in the name of the school district, public school, charter
9
school, or nonpublic school to be maintained for use when
10
necessary. Any supply of epinephrine injectors shall be
11
maintained in accordance with the manufacturer's instructions.
12

The school district, public school, charter school, or
13
nonpublic school shall maintain a supply of an opioid
14
antagonist in any secure location where an individual may have
15
an opioid overdose, unless there is a shortage of opioid
16
antagonists, in which case the school district, public school,
17
charter school, or nonpublic school shall make a reasonable
18
effort to maintain a supply of an opioid antagonist. Unless
19
the school district, public school, charter school, or
20
nonpublic school is able to obtain opioid antagonists without
21
a prescription, a health care professional who has been
22
delegated prescriptive authority for opioid antagonists in
23
accordance with Section 5-23 of the Substance Use Disorder Act
24
shall prescribe opioid antagonists in the name of the school
25
district, public school, charter school, or nonpublic school,
26
to be maintained for use when necessary. Any supply of opioid

SB3051 Enrolled
- 13 -
LRB104 16562 LNS 29960 b
1
antagonists shall be maintained in accordance with the
2
manufacturer's instructions.
3

The school district, public school, charter school, or
4
nonpublic school may maintain a supply of asthma medication in
5
any secure location that is accessible before, during, or
6
after school where a person is most at risk, including, but not
7
limited to, a classroom or the nurse's office. A physician, a
8
physician assistant who has prescriptive authority under
9
Section 7.5 of the Physician Assistant Practice Act of 1987,
10
or an advanced practice registered nurse who has prescriptive
11
authority under Section 65-40 of the Nurse Practice Act may
12
prescribe undesignated asthma medication in the name of the
13
school district, public school, charter school, or nonpublic
14
school to be maintained for use when necessary. Any supply of
15
undesignated asthma medication must be maintained in
16
accordance with the manufacturer's instructions.
17

The school district, public school, charter school, or
18
nonpublic school may maintain a supply of undesignated
19
glucagon in any secure location that is accessible before,
20
during, or after school where a person is most at risk,
21
including, but not limited to, a classroom or the nurse's
22
office. A physician, a physician assistant who has
23
prescriptive authority under Section 7.5 of the Physician
24
Assistant Practice Act of 1987, or an advanced practice
25
registered nurse who has prescriptive authority under Section
26
65-40 of the Nurse Practice Act may prescribe undesignated

SB3051 Enrolled
- 14 -
LRB104 16562 LNS 29960 b
1
glucagon in the name of the school district, public school,
2
charter school, or nonpublic school to be maintained for use
3
when necessary. Any supply of undesignated glucagon must be
4
maintained in accordance with the manufacturer's instructions.

5

A school district that provides special educational
6
facilities for children with disabilities under Section
7
14-4.01 of this Code may maintain a supply of undesignated
8
oxygen tanks in any secure location that is accessible before,
9
during, and after school where a person with developmental
10
disabilities is most at risk, including, but not limited to,
11
classrooms and lunchrooms. A physician, a physician assistant
12
who has prescriptive authority in accordance with Section 7.5
13
of the Physician Assistant Practice Act of 1987, or an
14
advanced practice registered nurse who has prescriptive
15
authority in accordance with Section 65-40 of the Nurse
16
Practice Act may prescribe undesignated oxygen tanks in the
17
name of the school district that provides special educational
18
facilities for children with disabilities under Section
19
14-4.01 of this Code to be maintained for use when necessary.
20
Any supply of oxygen tanks shall be maintained in accordance
21
with the manufacturer's instructions and with the local fire
22
department's rules.
23

(f-3) Whichever entity initiates the process of obtaining
24
undesignated epinephrine injectors and providing training to
25
personnel for carrying and administering undesignated
26
epinephrine injectors shall pay for the costs of the

SB3051 Enrolled
- 15 -
LRB104 16562 LNS 29960 b
1
undesignated epinephrine injectors.
2

(f-5) Upon any administration of an epinephrine injector,
3
a school district, public school, charter school, or nonpublic
4
school must immediately activate the EMS system and notify the
5
student's parent, guardian, or emergency contact, if known.
6

Upon any administration of an opioid antagonist, a school
7
district, public school, charter school, or nonpublic school
8
must immediately activate the EMS system and notify the
9
student's parent, guardian, or emergency contact, if known.
10

(f-10) Within 24 hours of the administration of an
11
undesignated epinephrine injector, a school district, public
12
school, charter school, or nonpublic school must notify the
13
physician, physician assistant, or advanced practice
14
registered nurse who provided the standing protocol and a
15
prescription for the undesignated epinephrine injector of its
16
use.
17

Within 24 hours after the administration of an opioid
18
antagonist, a school district, public school, charter school,
19
or nonpublic school must notify the health care professional
20
who provided the prescription for the opioid antagonist of its
21
use.
22

Within 24 hours after the administration of undesignated
23
asthma medication, a school district, public school, charter
24
school, or nonpublic school must notify the student's parent
25
or guardian or emergency contact, if known, and the physician,
26
physician assistant, or advanced practice registered nurse who

SB3051 Enrolled
- 16 -
LRB104 16562 LNS 29960 b
1
provided the standing protocol and a prescription for the
2
undesignated asthma medication of its use. The district or
3
school must follow up with the school nurse, if available, and
4
may, with the consent of the child's parent or guardian,
5
notify the child's health care provider of record, as
6
determined under this Section, of its use.
7

Within 24 hours after the administration of undesignated
8
glucagon, a school district, public school, charter school, or
9
nonpublic school must notify the student's parent or guardian
10
or emergency contact, if known, and the physician, physician
11
assistant, or advanced practice registered nurse who provided
12
the standing protocol and a prescription for the undesignated
13
glucagon of its use.

14

(g) Prior to the administration of an undesignated
15
epinephrine injector, trained personnel must submit to the
16
school's administration proof of completion of a training
17
curriculum to recognize and respond to anaphylaxis that meets
18
the requirements of subsection (h) of this Section. Training
19
must be completed annually. The school district, public
20
school, charter school, or nonpublic school must maintain
21
records related to the training curriculum and trained
22
personnel.
23

Prior to the administration of an opioid antagonist,
24
trained personnel must submit to the school's administration
25
proof of completion of a training curriculum to recognize and
26
respond to an opioid overdose, which curriculum must meet the

SB3051 Enrolled
- 17 -
LRB104 16562 LNS 29960 b
1
requirements of subsection (h-5) of this Section. The school
2
district, public school, charter school, or nonpublic school
3
must maintain records relating to the training curriculum and
4
the trained personnel.
5

Prior to the administration of undesignated asthma
6
medication, trained personnel must submit to the school's
7
administration proof of completion of a training curriculum to
8
recognize and respond to respiratory distress, which must meet
9
the requirements of subsection (h-10) of this Section.
10
Training must be completed annually, and the school district,
11
public school, charter school, or nonpublic school must
12
maintain records relating to the training curriculum and the
13
trained personnel.
14

Prior to the administration of undesignated glucagon,
15
trained personnel must submit to the school's administration
16
proof of completion of a training curriculum to recognize and
17
respond to severe hypoglycemia emergencies, which must meet
18
the requirements of subsection (h-15) of this Section.
19
Training must be completed annually, and the school district,
20
public school, charter school, or nonpublic school must
21
maintain records relating to the training curriculum and the
22
trained personnel.

23

(h) A training curriculum to recognize and respond to
24
anaphylaxis, including the administration of an undesignated
25
epinephrine injector, may be conducted online or in person.
26

Training shall include, but is not limited to:

SB3051 Enrolled
- 18 -
LRB104 16562 LNS 29960 b
1

(1) how to recognize signs and symptoms of an allergic
2

reaction, including anaphylaxis;
3

(2) how to administer an epinephrine injector; and
4

(3) a test demonstrating competency of the knowledge
5

required to recognize anaphylaxis and administer an
6

epinephrine injector.
7

Training may also include, but is not limited to:
8

(A) a review of high-risk areas within a school and
9

its related facilities;
10

(B) steps to take to prevent exposure to allergens;
11

(C) emergency follow-up procedures, including the
12

importance of calling 9-1-1 or, if 9-1-1 is not available,
13

other local emergency medical services;
14

(D) how to respond to a student with a known allergy,
15

as well as a student with a previously unknown allergy;
16

(E) other criteria as determined in rules adopted
17

pursuant to this Section; and
18

(F) any policy developed by the State Board of
19

Education under Section 2-3.190.
20

In consultation with statewide professional organizations
21
representing physicians licensed to practice medicine in all
22
of its branches, registered nurses, and school nurses, the
23
State Board of Education shall make available resource
24
materials consistent with criteria in this subsection (h) for
25
educating trained personnel to recognize and respond to
26
anaphylaxis. The State Board may take into consideration the

SB3051 Enrolled
- 19 -
LRB104 16562 LNS 29960 b
1
curriculum on this subject developed by other states, as well
2
as any other curricular materials suggested by medical experts
3
and other groups that work on life-threatening allergy issues.
4
The State Board is not required to create new resource
5
materials. The State Board shall make these resource materials
6
available on its Internet website.
7

(h-5) A training curriculum to recognize and respond to an
8
opioid overdose, including the administration of an opioid
9
antagonist, may be conducted online or in person. The training
10
must comply with any training requirements under Section 5-23
11
of the Substance Use Disorder Act and the corresponding rules.
12
It must include, but is not limited to:
13

(1) how to recognize symptoms of an opioid overdose;
14

(2) information on drug overdose prevention and
15

recognition;
16

(3) how to perform rescue breathing and resuscitation;
17

(4) how to respond to an emergency involving an opioid
18

overdose;
19

(5) opioid antagonist dosage and administration;
20

(6) the importance of calling 9-1-1 or, if 9-1-1 is
21

not available, other local emergency medical services;
22

(7) care for the overdose victim after administration
23

of the overdose antagonist;
24

(8) a test demonstrating competency of the knowledge
25

required to recognize an opioid overdose and administer a
26

dose of an opioid antagonist; and

SB3051 Enrolled
- 20 -
LRB104 16562 LNS 29960 b
1

(9) other criteria as determined in rules adopted
2

pursuant to this Section.
3

(h-10) A training curriculum to recognize and respond to
4
respiratory distress, including the administration of
5
undesignated asthma medication, may be conducted online or in
6
person. The training must include, but is not limited to:
7

(1) how to recognize symptoms of respiratory distress
8

and how to distinguish respiratory distress from
9

anaphylaxis;
10

(2) how to respond to an emergency involving
11

respiratory distress;
12

(3) asthma medication dosage and administration;
13

(4) the importance of calling 9-1-1 or, if 9-1-1 is
14

not available, other local emergency medical services;
15

(5) a test demonstrating competency of the knowledge
16

required to recognize respiratory distress and administer
17

asthma medication; and
18

(6) other criteria as determined in rules adopted
19

under this Section.
20

(h-15) A training curriculum to recognize and respond to
21
severe hypoglycemia emergencies, including the administration
22
of undesignated glucagon, may be conducted online or in
23
person. The training must include, but is not limited to:
24

(1) how to recognize the symptoms of severe
25

hypoglycemia emergencies;
26

(2) how to respond to an emergency involving severe

SB3051 Enrolled
- 21 -
LRB104 16562 LNS 29960 b
1

hypoglycemia;
2

(3) glucagon dosage and administration;
3

(4) the importance of calling 9-1-1 or, if 9-1-1 is
4

not available, other local emergency medical services;
5

(5) a test demonstrating competency of the knowledge
6

required to recognize severe hypoglycemia emergencies and
7

administer glucagon; and
8

(6) other criteria as determined in rules adopted
9

under this Section.

10

(i) Within 3 days after the administration of an
11
undesignated epinephrine injector by a school nurse, trained
12
personnel, or a student at a school or school-sponsored
13
activity, the school must report to the State Board of
14
Education in a form and manner prescribed by the State Board
15
the following information:
16

(1) age and type of person receiving epinephrine
17

(student, staff, visitor);
18

(2) any previously known diagnosis of a severe
19

allergy;
20

(3) trigger that precipitated allergic episode;
21

(4) location where symptoms developed;
22

(5) number of doses administered;
23

(6) type of person administering epinephrine (school
24

nurse, trained personnel, student); and
25

(7) any other information required by the State Board.
26

If a school district, public school, charter school, or

SB3051 Enrolled
- 22 -
LRB104 16562 LNS 29960 b
1
nonpublic school maintains or has an independent contractor
2
providing transportation to students who maintains a supply of
3
undesignated epinephrine injectors, then the school district,
4
public school, charter school, or nonpublic school must report
5
that information to the State Board of Education upon adoption
6
or change of the policy of the school district, public school,
7
charter school, nonpublic school, or independent contractor,
8
in a manner as prescribed by the State Board. The report must
9
include the number of undesignated epinephrine injectors in
10
supply.
11

(i-5) Within 3 days after the administration of an opioid
12
antagonist by a school nurse or trained personnel, the school
13
must report to the State Board of Education, in a form and
14
manner prescribed by the State Board, the following
15
information:
16

(1) the age and type of person receiving the opioid
17

antagonist (student, staff, or visitor);
18

(2) the location where symptoms developed;
19

(3) the type of person administering the opioid
20

antagonist (school nurse or trained personnel); and
21

(4) any other information required by the State Board.
22

(i-10) Within 3 days after the administration of
23
undesignated asthma medication by a school nurse, trained
24
personnel, or a student at a school or school-sponsored
25
activity, the school must report to the State Board of
26
Education, on a form and in a manner prescribed by the State

SB3051 Enrolled
- 23 -
LRB104 16562 LNS 29960 b
1
Board of Education, the following information:
2

(1) the age and type of person receiving the asthma
3

medication (student, staff, or visitor);
4

(2) any previously known diagnosis of asthma for the
5

person;
6

(3) the trigger that precipitated respiratory
7

distress, if identifiable;
8

(4) the location of where the symptoms developed;
9

(5) the number of doses administered;
10

(6) the type of person administering the asthma
11

medication (school nurse, trained personnel, or student);
12

(7) the outcome of the asthma medication
13

administration; and
14

(8) any other information required by the State Board.
15

(i-15) Within 3 days after the administration of
16
undesignated glucagon by a school nurse or trained personnel,
17
the school must report to the State Board of Education, on a
18
form and in a manner prescribed by the State Board of
19
Education, the following information:
20

(1) the age of the student receiving the undesignated
21

glucagon;
22

(2) any previously known diagnosis of severe
23

hypoglycemia for the person;
24

(3) the trigger that precipitated the severe
25

hypoglycemia emergency, if identifiable;
26

(4) the location of where the symptoms developed;

SB3051 Enrolled
- 24 -
LRB104 16562 LNS 29960 b
1

(5) the number of doses administered;
2

(6) the type of person administering the undesignated
3

glucagon (school nurse or trained personnel);
4

(7) the outcome of the glucagon administration; and
5

(8) any other information required by the State Board.

6

(j) By October 1, 2015 and every year thereafter, the
7
State Board of Education shall submit a report to the General
8
Assembly identifying the frequency and circumstances of
9
undesignated epinephrine and undesignated asthma medication
10
administration during the preceding academic year. Beginning
11
with the 2017 report, the report shall also contain
12
information on which school districts, public schools, charter
13
schools, and nonpublic schools maintain or have independent
14
contractors providing transportation to students who maintain
15
a supply of undesignated epinephrine injectors. This report
16
shall be published on the State Board's Internet website on
17
the date the report is delivered to the General Assembly.
18

(j-5) Annually, each school district, public school,
19
charter school, or nonpublic school shall request an asthma
20
action plan from the parents or guardians of a pupil with
21
asthma. If provided, the asthma action plan must be kept on
22
file in the office of the school nurse or, in the absence of a
23
school nurse, the school administrator. Copies of the asthma
24
action plan may be distributed to appropriate school staff who
25
interact with the pupil on a regular basis, and, if
26
applicable, may be attached to the pupil's federal Section 504

SB3051 Enrolled
- 25 -
LRB104 16562 LNS 29960 b
1
plan or individualized education program plan.
2

(j-10) To assist schools with emergency response
3
procedures for asthma, the State Board of Education, in
4
consultation with statewide professional organizations with
5
expertise in asthma management and a statewide organization
6
representing school administrators, shall develop a model
7
asthma episode emergency response protocol before September 1,
8
2016. Each school district, charter school, and nonpublic
9
school shall adopt an asthma episode emergency response
10
protocol before January 1, 2017 that includes all of the
11
components of the State Board's model protocol.
12

(j-15) (Blank).
13

(j-20) On or before October 1, 2016 and every year
14
thereafter, the State Board of Education shall submit a report
15
to the General Assembly and the Department of Public Health
16
identifying the frequency and circumstances of opioid
17
antagonist administration during the preceding academic year.
18
This report shall be published on the State Board's Internet
19
website on the date the report is delivered to the General
20
Assembly.
21

(j-25) On or before October 1, 2027 and every year
22
thereafter, the State Board of Education shall submit a report
23
to the General Assembly and the Department of Public Health
24
identifying the frequency and circumstances of undesignated
25
glucagon administration during the preceding school year. This
26
report shall be published on the State Board's Internet

SB3051 Enrolled
- 26 -
LRB104 16562 LNS 29960 b
1
website on the date the report is delivered to the General
2
Assembly.

3

(k) The State Board of Education may adopt rules necessary
4
to implement this Section.
5

(l) Nothing in this Section shall limit the amount of
6
epinephrine injectors that any type of school or student may
7
carry or maintain a supply of.
8
(Source: P.A. 102-413, eff. 8-20-21; 102-813, eff. 5-13-22;
9
103-175, eff. 6-30-23; 103-196, eff. 1-1-24; 103-348, eff.
10
1-1-24; 103-542, eff. 7-1-24 (see Section 905 of P.A. 103-563
11
for effective date of P.A. 103-542); 103-605, eff. 7-1-24.)

Footer

Disclaimer

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.

Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.
Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn